MedTrace Logo

Ranibizumab Treatment for Age-Related Macular Degeneretion

NCT02158624 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-06-09

No results posted yet for this study

Summary

To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

Conditions

  • Visual Disorder Due to Age-related Macula Degeneration

Interventions

DRUG

Intravitreal Lucentis 0.5mg

Sponsors & Collaborators

  • University of Occupational and Environmental Health

    collaborator OTHER

  • Kurume University

    collaborator OTHER

  • Fukuoka University

    collaborator OTHER

  • Clinical Research Support Center Kyush

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Kyushu University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-04-30
Completion
2015-12-31

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02158624 on ClinicalTrials.gov